Sreenivas Nannapaneni
Overview
Explore the profile of Sreenivas Nannapaneni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
527
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shu L, Wang D, Nannapaneni S, Sun Y, Griffith C, Wang X, et al.
Oral Oncol
. 2021 Oct;
122:105546.
PMID: 34700281
Objective: To test the potential ability of tipifarnib to impair proliferation and to enhance the activity of the EGFR inhibitor cetuximab in wild-type H-Ras HNSCC, which accounts for the majority...
2.
Amin A, Wang D, Nannapaneni S, Lamichhane R, Chen Z, Shin D
Oncol Rep
. 2021 Apr;
45(5).
PMID: 33864659
Despite widespread interest in chemoprevention and therapy due to the high margin of safety of dietary natural compounds, clinical intervention with single agents has failed to yield the expected outcomes,...
3.
Nannapaneni S, Griffith C, Magliocca K, Chen W, Lyu X, Chen Z, et al.
PLoS One
. 2021 Feb;
16(2):e0247498.
PMID: 33626078
Fibroblast growth factor receptor 3 (FGFR3) is expressed in squamous cell carcinoma of the head and neck (SCCHN) including oropharyngeal squamous cell carcinoma (OPSCC) and is a potential therapeutic target....
4.
Wang D, Lu Y, Nannapaneni S, Griffith C, Steuer C, Qian G, et al.
Oral Oncol
. 2020 Nov;
112:105074.
PMID: 33142224
Objective: We aimed to develop novel combinations of inhibitors targeting EGFR family members and c-Met for the treatment of recurrent SCCHN. Materials And Methods: Three different c-Met inhibitors in combination...
5.
Shin D, Nannapaneni S, Patel M, Shi Q, Liu Y, Chen Z, et al.
Clin Cancer Res
. 2020 Sep;
26(22):5860-5868.
PMID: 32943457
Purpose: On the basis of synergistic effects between green tea polyphenon E (PPE) and EGFR-tyrosine kinase inhibitor in preclinical studies, we conducted a phase Ib study of the PPE and...
6.
Wang D, Muller S, Amin A, Huang D, Su L, Hu Z, et al.
Clin Cancer Res
. 2020 Sep;
26(18):5052.
PMID: 32934033
No abstract available.
7.
Rahman M, Wang P, Zhao Z, Wang D, Nannapaneni S, Zhang C, et al.
Angew Chem Int Ed Engl
. 2020 Jul;
59(31):12575.
PMID: 32691956
No abstract available.
8.
Evans M, Baddour Jr H, Magliocca K, Muller S, Nannapaneni S, Chen A, et al.
Cancer Med
. 2018 Dec;
8(1):147-154.
PMID: 30575303
Background: There is conflicting evidence regarding the role of peritumoral lymphatic vessel density (LVD) and blood microvessel density (MVD) in the metastasis and prognosis of head and neck squamous cell...
9.
Lesinski G, Nannapaneni S, Griffith C, Patel M, Chen W, Chen Z, et al.
Head Neck Pathol
. 2018 Sep;
13(3):304-312.
PMID: 30191505
This study addresses the hypothesis that IL-6/STAT3 signaling is of clinical relevance in oropharyngeal squamous cell carcinoma (OPSCC). We evaluated relationships between key components of this pathway in tumors from...
10.
Steuer C, Griffith C, Nannapaneni S, Patel M, Liu Y, Magliocca K, et al.
Mol Cancer Ther
. 2018 Feb;
17(3):710-716.
PMID: 29440293
We explored potential associations of the PD-1/PD-L1/PD-L2 pathway with clinical characteristics, outcome, and expression of EGFR, HER2, HER3 in oropharyngeal squamous cell carcinoma (OPSCC) using an institutional database. Protein expression...